drugset / Trial / NCT02332031

Sorafenib Drug Drug Interaction Study in Healthy Male Subjects

NCT02332031

Phase 1 Completed 25 enrolled Bayer
Non-randomizedSingle-groupOpen-label

Summary

To evaluate the effect of levothyroxine on the absorption, distribution, metabolization and elimination of sorafenib and safety in healthy male subjects

Timeline

Start
2015-02
Primary completion
2015-06
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Levothyroxine Other / unclassified 300 ug Oral
Subject Sorafenib Small molecule 400 mg Oral

Indications

No indication recorded.